11th International Congress on Targeted Anticancer Therapies (TAT)
نویسنده
چکیده
The 11th International Congress on Targeted Anticancer Therapies (TAT) was held in Paris for the second time under the presidency of Professor Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France. The TAT Congress was co-sponsored by the Amsterdam-based NDDO Education Foundation and European Society for Medical Oncology (ESMO). NDDO is the primary organizer of all meetings in the TAT congress series, which aims to disseminate findings from experimental and clinical studies on the prevention and treatment of different types of cancer. ESMO is the foremost European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment. The TAT Congress is also sponsored by the USA National Cancer Institute (NCI)/Center for Cancer Research, which is the world's largest organisation dedicated to cancer research.
منابع مشابه
11th International Congress on Targeted Anticancer Therapies
paris, france, 4–6 March 2013 The Targeted Anticancer Therapies (TAT) conference provides a forum for in-depth discussion of emerging targeted agents for the treatment of cancer. TAT conferences are characterized by focus on emerging innovative agents with a cancer-specific molecular target, gathering the world’s leading oncology Phase I investigators. They attract a mix of professionals with d...
متن کاملVolume 4, Supplement 1, Summer 2010 (presented at 11th Royan Congress on Reproductive Biomedicine and 5th Royan Nursing and Midwifery Seminar)
متن کامل
Targeted alpha anticancer therapies: update and future prospects
Targeted alpha therapy (TAT) is an emerging option for local and systemic cancer treatment. Preclinical research and clinical trials show that alpha-emitting radionuclides can kill targeted cancer cells while sparing normal cells, thus reducing toxicity. (223)RaCl2 (Xofigo(®)) is the first alpha emitting radioisotope to gain registration in the US for palliative therapy of prostate cancer bone ...
متن کاملNuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles.
Most present nanodrug delivery systems have been developed to target cancer cells but rarely nuclei. However, nuclear-targeted drug delivery is expected to kill cancer cells more directly and efficiently. In this work, TAT peptide has been employed to conjugate onto mesoporous silica nanoparticles (MSNs-TAT) with high payload for nuclear-targeted drug delivery for the first time. Monodispersed ...
متن کامل